[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Maria Marta Piskorz\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100574224","exocrine-pancreatic-insufficiency-and-functional-dyspepsia-100574224",false,"NCT06756503","Exocrine Pancreatic Insufficiency and Functional Dyspepsia","Prevalence and Clinical Characteristics of Exocrine Pancreatic Insufficiency in Patients With Functional Dyspepsia","Inclusion Criteria:\n\n* Patients over 18 years of age diagnosed with functional dyspepsia based on Rome IV criteria, who have been excluded for organic, metabolic, and medication-related causes (NSAIDs), and who test negative for H. pylori.\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Organic diseases of the digestive tract (celiac disease, inflammatory bowel diseases, neoplasms, positive for H. pylori)\n* Uncontrolled systemic diseases (diabetes mellitus, hypo- or hyperthyroidism, cancer, etc.)\n* Lack of informed consent\n* Severe psychiatric disorders, defined based on the DSM-5","ALL","18 Years","65 Years",{"count":20,"type":21},65,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the prevalence of exocrine pancreatic insufficiency in patients with functional dyspepsia .\n\n. The main questions it aims to answer are: What is the prevalence of exocrine pancreatic insufficiency (EPI) in patients with functional dyspepsia? Wich are the clinical characteristics associated with (EPI) in patients with functional dyspepsia? Patients diagnosed with functional dyspepsia will undergo an evaluation of clinical symptoms and fecal elastase determination. In those with fecal elastase levels below 100 µg\u002Fg, an endoscopic ultrasound and other assessments will be performed to define the cause of exocrine pancreatic insufficiency (EPI).",[25,26],"Exocrine Pancreatic Insufficiency","Dyspepsia",[28,29,30],"Exocrine pancreatic insufficiency","Functional dyspepsia","Fecal elastase","NOT_YET_RECRUITING","2025-08-05",{"date":34,"type":35},"2025-08-08","ACTUAL",{"date":37,"type":21},"2025-09-01",{"date":39,"type":21},"2026-08-01",{"name":41,"class":42},"Maria Marta Piskorz","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100574289","fatty-liver-and-pancreatic-steatosis-100574289","NCT06757348","Fatty Liver and Pancreatic Steatosis","Association Between Fatty Liver and Pancreatic Steatosis in Patients With Metabolic Syndrome","Inclusion Criteria:\n\n* Patients over 18 years old with a diagnosis of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).\n\nExclusion Criteria:\n\n* \\- Alcohol consumption \\>20 g\u002Fday in women, \\>30 g\u002Fday in men\n* Chronic hepatitis B or C infection\n* Autoimmune liver diseases: autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis\n* Hereditary hemochromatosis\n* Wilson's disease\n* Alpha-1 antitrypsin deficiency\n* Celiac disease\n* Uncontrolled thyroid disease\n* Active or chronic infectious disease\n* Active cancer or ongoing treatment\n* Chronic renal insufficiency\n* Pregnancy\u002Flactation\n* Insufficient data\n* Patients who do not complete follow-up",{"count":51,"type":21},61,"The goal of this observational study is to determine the prevalence of pancreatic steatosis in patients with fatty liver and determine the prevalence of exocrine pancreatic insufficiency (EPI) in these patients.\n\nParticipants with fatty liver and metabolic syndrome will undergo fecal elastase measurement and endoscopic ultrasound (EUS).",[25,54,55],"Fatty Liver, Nonalcoholic","Pancreatic Steatosis",[57,58,59],"Fatty liver","Pancreatic steatosis","Metabolic syndrome",{"date":61,"type":35},"2025-08-06",{"date":37,"type":21},{"date":64,"type":21},"2026-03-01",{"name":41,"class":42},1,""]